BRIEF-Roivant Reports Positive Topline Results From ADORING 2 Atopic Dermatitis Phase 3 Trial Of VTAMA Cream
Reuters · 03/15 12:02
BRIEF-Roivant To Host Investor Call At 800 Am Et On Wednesday, March 15 To Review Results From Adoring 2 Phase 3 Trial In Atopic Dermatitis
Reuters · 03/14 22:53
Moderna loses bid to shift liability in COVID-19 vaccine patent case
Reuters · 03/10 23:31
BRIEF-Covant Therapeutics Announces Formation Of Its Scientific Advisory Board To Support Platform And Pipeline Advancement
Reuters · 03/07 13:15
BRIEF-Roivant Sciences Says Founder Vivek Ramaswamy Has Stepped Down From Company's Board Of Directors
Reuters · 02/22 01:34
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
Reuters · 02/15 16:57
Roivant Sciences prices upsized public offering of $200M
Seeking Alpha · 02/03 10:51
BRIEF-Roivant Sciences Prices Upsized Underwritten Public Offering Of 26.7 Million Of Common Shares At $7.50/Share
Reuters · 02/03 02:17
BRIEF-Roivant Sciences Provides An Update On Its Financial Results For The Third Quarter
Reuters · 02/01 23:54
BRIEF-Roivant Sciences Announces Proposed Public Offering Of Common Shares
Reuters · 02/01 22:56
BRIEF-Roivant Announces Results From The Induction Period Of Phase 2B Study Of Subcutaneous Rvt-3101 For The Treatment Of Ulcerative Colitis
Reuters · 01/04 11:08
Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant
Edison Partners, a leading growth equity investment firm, today announced it is leading a $21 million investment round in Lokavant, the leading clinical trial intelligence company.
PR Newswire · 12/07/2022 11:30
Pfizer partners with Clear Creek Bio to develop oral COVID-19 drug
Reuters · 12/06/2022 13:40
UPDATE 1-Roivant, Pfizer launch unit to develop inflammatory disease drug
Reuters · 12/01/2022 13:33
BRIEF-Roivant Sciences Ltd - Expects That This Collaboration Will Not Impact Co’S Previously Announced Cash Runway Into Second Half Of Calendar Year 2025
Reuters · 12/01/2022 13:18
Roivant, Pfizer create unit for inflammatory disease drug
Reuters · 12/01/2022 13:12
BRIEF-Roivant Sciences Reports Financial Results For Q2
Reuters · 11/14/2022 13:09
BRIEF-Roivant Sciences Announces Pricing Of Primary And Secondary Public Equity Offering
Reuters · 11/08/2022 11:16
BRIEF-Roivant Sciences Announces Proposed Public Equity Offering
Reuters · 11/07/2022 21:57
UPDATE 3-Japan's Sumitomo Pharma to buy rest of Myovant in sweetened deal
Reuters · 10/24/2022 11:00
Webull provides a variety of real-time ROIVW stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.